4721 Emperor Boulevard
44 articles with Bioventus
National Institute for Health and Clinical Excellence Maintains Previous Recommendation for EXOGEN® Ultrasound Bone Healing System
EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process and promote fracture healing
Bioventus, a global leader in orthobiologic solutions, has agreed to a nationwide contract with UnitedHealthcare Employer & Individual commercial plans. Beginning October 1, 2019, UnitedHealthcare commercial plan members will have access to both DUROLANE and GELSYN-3, to treat knee osteoarthritis (OA) pain.
Bioventus, a global leader in orthobiologic solutions, is launching OSTEOAMP SELECT Fibers, an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons.
DUROLANE is a single-injection, hyaluronic acid product used for joint lubrication in the treatment of pain associated with knee osteoarthritis.
Bioventus, a global leader in orthobiologic solutions, is launching OSTEOMATRIX+, its next generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications.
Bioventus, a global leader in orthobiologic solutions, today announced the appointment of Susan M. Stalnecker, former Vice President and Treasurer, E.I. du Pont de Nemours and Company, to the company’s Board of Managers, replacing Michael Minogue.
Bioventus Enters Into Definitive Agreement to Divest BMP Development Program to Viscogliosi Brothers, LLC
Bioventus has entered into a definitive agreement to divest its next generation bone morphogenetic protein development program to a new company formed by Viscogliosi Brothers, LLC (VB), a private equity investment firm focused on developing innovative neuromusculoskeletal technologies.
TissueTech Inc., pioneers of the development and clinical application of amniotic tissue-based products, announced today the appointment of Dr. Frank Young as Executive Vice President of Regulatory Affairs.
Bioventus, a global leader in orthobiologic solutions, has entered into an agreement with LifeLink Tissue Bank, a division of LifeLink Foundation, Inc. headquartered in Tampa, FL, to co-develop a next generation bone allograft solution for use in spine and trauma surgery.
Under terms of this new agreement, Bioventus will be the exclusive distributor of SUPARTZ FX in the US through May 2028.
Bioventus, a global leader in orthobiologics, today has launched a new version of EXOGEN.com, the product website for its EXOGEN Ultrasound Bone Healing System.
Bioventus Names Greg Anglum Senior Vice President And Chief Financial Officer, Tony D’Adamio Senior Vice President And General Counsel
Bioventus Release: Meta-Analysis Reveals LIPUS As Alternative To Surgery For Established Nonunion Fractures